Uncover key drivers, emerging technologies, and competitive movements shaping the bronchiolitis obliterans syndrome market from 2026–2035 with trusted insights from The Business Research Company
How is the Bronchiolitis Obliterans Syndrome Market size predicted to change over the forecast window of 2026–2035?
The market size for bronchiolitis obliterans syndrome has experienced substantial growth in recent years. Its valuation is projected to increase from $1.59 billion in 2025 to $1.73 billion in 2026, advancing at a compound annual growth rate (CAGR) of 9.1%. This historical growth can be linked to several factors, including the rise in organ transplantation, occurrences of chronic graft rejection, improvements in hospital pulmonary care, the application of immunosuppressant therapies, and the limitations surrounding early diagnostics.
The bronchiolitis obliterans syndrome market size is projected to experience robust expansion in the coming years. This market is anticipated to reach $2.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.7%. The anticipated growth during this period stems from factors such as transplant procedure growth, advancements in early detection technologies, the emergence of personalized immunotherapy, the establishment of specialty respiratory centers, and enhanced long-term patient management. Key developments shaping the forecast period encompass increased monitoring post transplantation, the ongoing growth of immunosuppressive therapies, wider expansion of early diagnostic testing, a strong focus on preserving long-term lung function, and a rising demand for specialized pulmonary care.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24488&type=smp
Which Drivers Are Contributing To The Expansion Of The Bronchiolitis Obliterans Syndrome Market?
The expansion of lung transplantation procedures is anticipated to fuel the future growth of the bronchiolitis obliterans syndrome market. Lung transplantation involves a surgical process where a patient’s impaired or non-functional lung is substituted with a healthy donor lung to enhance respiratory function. The rise in these transplantations can be attributed to enhancements in surgical methods, which have considerably boosted success rates and minimized complications, thereby making the procedure safer and more accessible for those who require it. This surgical intervention effectively manages advanced bronchiolitis obliterans syndrome by replacing diseased lungs with healthy ones, leading to improved breathing and overall lung function. As an illustration, the Organ Procurement and Transplantation Network, a US-based non-profit scientific and educational entity, reported in January 2025 that lung transplants experienced their most significant proportional increase, rising from 3,026 transplants in 2023 to 3,340 in 2024, representing a 10.4 percent growth. Consequently, the increasing volume of lung transplants is a key driver for the expansion of the bronchiolitis obliterans syndrome market.
What Segment Classifications Make Up The Bronchiolitis Obliterans Syndrome Market?
The bronchiolitis obliterans syndrome market covered in this report is segmented –
1) By Treatment Type: Medication, Oxygen Therapy, Lung Transplant
2) By Diagnosis: Pulmonary Function Tests, Imaging Tests, Lung Biopsy, Other Diagnosis
3) By Disease Type: Acute Bronchiolitis, Chronic Bronchiolitis Obliterans Syndrome
4) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users
Subsegments:
1) By Medication: Immunosuppressants, Corticosteroids, Antibiotics, Bronchodilators, Anti-Inflammatory Agents
2) By Oxygen Therapy: Continuous Oxygen Therapy, Intermittent Oxygen Therapy, Portable Oxygen Therapy, Hyperbaric Oxygen Therapy
3) By Lung Transplant: Single Lung Transplant, Double Lung Transplant, Living Donor Lung Transplant, Retransplantation
Which Trends Are Influencing The Performance And Direction Of The Bronchiolitis Obliterans Syndrome Market?
Leading companies in the bronchiolitis obliterans syndrome market are concentrating on developing innovative solutions, such as at-home nebulized therapy, to improve medication adherence and slow disease progression through targeted, continuous treatment. This therapy involves using a nebulizer to transform liquid medication into a breathable mist for direct delivery to the lungs. This convenient, self-administered treatment allows for effective management of respiratory conditions from the comfort of home. For instance, in March 2023, Renovion, Inc., a US-based clinical-stage pharmaceutical company, launched ARINA-1, which received Food and Drug Administration (FDA) Fast Track Designation for its potential to prevent the progression of bronchiolitis obliterans syndrome (BOS) in patients with bilateral lung transplants. This regulatory milestone emphasizes ARINA-1’s capability to address a crucial unmet medical need in transplant medicine. The Fast Track status facilitates more frequent communication with the FDA and prioritizes ARINA-1 for accelerated development and review, reflecting Renovion’s dedication to advancing respiratory health through innovative, patient-focused therapeutics.
Which Leading Companies Dominate The Bronchiolitis Obliterans Syndrome Market Share?
Major companies operating in the bronchiolitis obliterans syndrome market are Novartis AG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, AstraZeneca plc, Sanofi S.A., Johnson & Johnson (Janssen), AbbVie Inc., Bristol-Myers Squibb Company, Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Ltd., Lupin Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Chiesi Farmaceutici S.p.A., Vertex Pharmaceuticals Incorporated, United Therapeutics Corporation, Insmed Incorporated, Viatris Inc., Zydus Lifesciences Ltd., Cadila Pharmaceuticals Ltd.
Access The Complete Report For Deeper Market Insights:
How Does The Bronchiolitis Obliterans Syndrome Market Perform Across Major Global Regions?
North America was the largest region in the bronchiolitis obliterans syndrome market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bronchiolitis obliterans syndrome market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Bronchiolitis Obliterans Syndrome Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=24488&type=smp
Browse Through More Reports Similar to the Global Bronchiolitis Obliterans Syndrome Market 2026, By The Business Research Company
Bronchitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/bronchitis-treatment-global-market-report
Reversible Airway Diseases Treatment Market Report 2026
Tracheitis Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/tracheitis-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model